ReviewCureus2025
Global Trends in the Research of Ulcerative Colitis Treatments (2021-2025): A Bibliometric Review.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ulcerative colitis (UC) is a chronic idiopathic inflammatory bowel disease characterized by mucosal ulceration and inflammation confined to the colonic epithelium. While colonoscopy remains the diagnostic gold standard, fecal calprotectin (FC) is a validated non-invasive biomarker. Therapeutic management encompasses immunosuppressive agents including anti-TNF biologics such as infliximab, vedolizumab, and ustekinumab for severe disease manifestations, whereas mild-to-moderate UC is managed with variable dosing regimens of 5-aminosalicylates administered via oral or rectal routes. This bibliometric analysis utilized the Web of Science (WoS) database to extract publication data spanning from January 1, 2021, to June 14, 2025, with subsequent exportation of tab-delimited datasets to VOSviewer (version 1.6.20) for comprehensive bibliometric visualization and analysis. Bibliometric analysis demonstrated that the People's Republic of China exhibited the highest publication output with predominantly recent scholarly contributions. Therapeutic research predominantly focused on biologic agents, specifically infliximab (677 publications), vedolizumab (269 publications), and ustekinumab (234 publications) over the five-year study period. Temporal analysis utilizing the WoS Core Collection revealed consistent publication growth, with 2024 demonstrating peak research output. Categorical distribution analysis indicated "Gastroenterology Hepatology" as the predominant research domain.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.